- Home
- NXPL vs COCH Comparison
NXPL vs COCH Comparison
Compare NXPL & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXPL | COCH |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Blank Checks |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 51.0M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXPL | COCH |
|---|---|---|
| Price | $8.19 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 39.5K | ★ 154.6K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,869,558.00 | $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.50 | ★ 7.11 |
| 52 Week Low | $0.34 | $0.36 |
| 52 Week High | $9.17 | $1.89 |
Technical Indicators
Market Signals| Indicator | NXPL | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 54.54 |
| Support Level | $5.54 | $0.63 |
| Resistance Level | $8.37 | $0.88 |
| Average True Range (ATR) | 0.60 | 0.05 |
| MACD | 0.26 | 0.01 |
| Stochastic Oscillator | 66.26 | 54.12 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.